#drug trial
Related Stories (6)
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026Humana agrees not to reference Teva's Israel ties at US drug trial - Reuters
Humana agrees not to reference Teva's Israel ties at US drug trial Reuters
August 13, 2026Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial - Reuters
Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial Reuters
July 31, 2026US FDA advisers back Replimune skin cancer drug trial data - Reuters
US FDA advisers back Replimune skin cancer drug trial data Reuters
July 30, 2026Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings - Reuters
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings Reuters
June 29, 2026Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
February 23, 2026Related Pages (5)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Novo Nordisk’s obesity drug falls short against Eli Lilly’s in trial
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing